

**WESTERN EUROPE**  
**PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE**  
**AND**  
**CRITICAL LIMB ISCHEMIA**  
**2017**

Mary L. Yost  
404-520-6652  
THE SAGE GROUP

THE SAGE GROUP, LLC  
23 Ridge Rd.  
Beaufort, SC 20097

Copyright Pending

2017

All rights reserved, including the right of reproduction  
in whole or in part in any form

## REFERENCES (FIRST & LAST PAGES)

1. Yost ML. Critical limb ischemia Volume II. Western Europe epidemiology. Atlanta (GA): THE SAGE GROUP; 2007.
2. Yost ML. Critical limb ischemia. Volume II. Western Europe epidemiology. Atlanta (GA): THE SAGE GROUP; 2010.
3. Yost ML. Critical limb ischemia Volume I. United States epidemiology. Atlanta (GA): THE SAGE GROUP; 2007 & 2010.
4. Yost ML. Critical limb ischemia Volume I. United States epidemiology. Atlanta (GA): THE SAGE GROUP; 2010.
5. Yost ML. Critical limb ischemia Volume I. United States epidemiology 2016 supplement. Beaufort (SC): THE SAGE GROUP; 2016.
6. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). *Lancet* 2005; 366: 1773-83.
7. Jensen SA, Vatten LJ, Myhre HO. The prevalence of critical lower limb ischemia in a population of 20,000 subjects 40-69 years of age. *Eur J Vasc Endovasc Surg* 2006; 32(1): 60-5.
8. Critical limb ischaemia: management and outcome. Report of a National survey. The Vascular Surgical Society of Great Britain and Ireland. *Eur J Vasc Endovasc Surg* 1995; 10:108-13.
9. International Diabetes Federation (IDF). Diabetes Atlas, executive summary, second edition 2003. [Internet. Accessed 2010] Available at: <http://www.eatlas.idf.org/webdata/docs/Atlas%202003-Summary.pdf>
10. International Diabetes Federation (IDF). Resources. Detailed data 2015. [Internet. Accessed 2017, Mar] Available at: <http://www.diabetesatlas.org/resources/2015-atlas.html>.
11. U.S. Census Bureau. International Data Base (IDB). Available at: <http://www.census.gov/population/international/data/idb/informationGateway.php>.
12. Nehler MR, Duval S, Diao L, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. *J Vasc Surg*. 2014 Sep; 60(3):686-95.e2.
13. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. *Int J Epidemiol*. 1996 Dec; 25(6):1172-81.
14. Heidemann C, Du Y, Schubert I et al. [Prevalence and temporal trend of known diabetes mellitus: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2013; 56(5-6):668-77.

105. Sørensen J, Ploug UJ. The cost of diabetes-related complications: registry-based analysis of days absent from work. *Economics Research International*. [Internet. Accessed 2017, Mar.] <http://dxdoiorg/101155/2013/618039> 2013: 8 pages.
106. Strøm H, Selmer R, Birkeland KI, et al. No increase in new users of blood glucose-lowering drugs in Norway 2006-2011: a nationwide prescription database study. *BMC Public Health*. 2014 May 29; 14:520.
107. Norwegian Institute of Public health. Diabetes in Norway - Public Health Report 2014. 4/18/2016. [Internet. Accessed 2017, Mar.] Available at: <https://www.fhi.no/en/op/public-health-report-2014/health--disease/diabetes-in-norway---public-health/>
108. IDF. Norway. [Internet. Accessed 2017, Mar.] Available at: <http://www.idf.org/membership/eur/norway>.

## CONTACT INFORMATION

### Research

Mary L. Yost  
President and Senior Analyst  
Telephone (404) 520-6652  
[yost@thesagegroup.us](mailto:yost@thesagegroup.us)

### Marketing

Harrington Witherspoon  
Senior Vice President  
Marketing  
Telephone (404) 816-0746  
[witherspoon@thesagegroup.us](mailto:witherspoon@thesagegroup.us)